| Name | Rosiglitazone |
|---|---|
| Synonyms |
Rosiglitazone Monomer
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione Rosiglitazone and its intermediates ROSIGLITAZONE HCL Rosiglitazone, >= RosigL Rosiglitazone > Rosiglitazone Rosiglitazone 2-[(2-benzoylphenyl)amino]-3-{4-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid RosiglitazoneBase/Hcl/Maleate Rosiglitazone 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione 5-(4-{2-[Methyl(2-pyridinyl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione AVANDIA ROSIGLIAZONE RosiglitazoneQ: What is Rosiglitazone Q: What is the CAS Number of Rosiglitazone Q: What is the storage condition of Rosiglitazone Q: What e the applications of Rosiglitazone Rosiglitazone (Avandia) ROSIGLITAZONE ROEIGLITAZONEMALEATE ROSIGLITAZONEHCL Rosiglitazone, 10 mM in DMSO 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Avandia Rosig (RS)-5-[4-(2-[Methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione diabetic,PP,neuroprotection,senescence,PPγ,Inhibitor,cancer,diabetes,Autophagy,BRL 49653,BRL-49653,HCC,antihyperglycemic,TRP Channel,bladder,Rosiglitazone,mellitus,Peroxisome proliferator-activated rectors,inhibit,ccinoma,smoke,Apoptosis,ovian cancer,Transient rector potential channels,hatocellul,Ferroptosis Rosiglitazone (base,meleate) 5-(4-[2-(METHYL-PYRIDIN-2-YL-AMINO)-ETHOXY]-BENZYL)-THIAZOLIDINE-2,4-DIONE 5-[[4-[2-[methyl(2-pyridinyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione hydrochloride Rosiglitazone, PPgamma agonist 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione roiglitazone Rosiglitazone free base 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) itazone Rosiglitazone Maleate 5-[4-[2-[methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-quinone Rosiglitazone - Bio-X MFCD00871760 Rosiglitazone 122-4 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzylidine]-2,4-thiazolidinedione 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-tiazolidinedione 5-[[4-[2-(methyl-pyridin-2-yl-amino)ethoxy]phenyl]methyl]thiazolidine-2,4-dione 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl] Rosiglitazone //BP ROSIGLIAZONE (5-{4-[2-(N-methyl-N-2-pyridyl)amino]-ethoxy}benzyl}-2,4-thiazolidinedione) |
| Description | Rosiglitazone (BRL49653) is a potent thiazolidinedione insulin sensitizer. Rosiglitazone is a selective PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. |
|---|---|
| Related Catalog | |
| Target |
PPARγ1:30 nM (EC50) PPARγ2:100 nM (EC50) |
| In Vitro | Rosiglitazone is a potent and selective activator of PPARγ, with EC50s of 30 nM and 100 nM for PPARγ1 and PPARγ2, respectively, and a Kd of appr 40 nM for PPARγ. Rosiglitazone (BRL49653, 0.1, 1,10 μM) promotes differentiation of C3H10T1/2 stem cells to adipocytes[1]. Rosiglitazone (Compound 6) activates PPARγ, with an EC50 of 60 nM[2]. Rosiglitazone (1 μM) activates PPARγ, which binds to NF-α1 promoter to activate gene transcription in neurons. Rosiglitazone (1 μM) also protects Neuro2A cells and hippocampal neurons against oxidative stress, and up-regulates BCL-2 expression in an NF-α1-dependent manner[3]. Rosiglitazone completely inhibits TRPM3 with IC50 values of 9.5 and 4.6 μM against nifedipine- and PregS-evoked activity, but such effects are not via PPARγ. Rosiglitazone inhibits TRPM2 at higher concentration, with an IC50 of appr 22.5 μM. Rosiglitazone is a strong stimulator of TRPC5 channels, with an EC50 of ∼30 μM[4]. |
| In Vivo | Rosiglitazone (5 mg/kg, p.o.) decreases the serum glucose in diabetic rats. Rosiglitazone also decreases IL-6, TNF-α, and VCAM-1 levels in diabetic group. Rosiglitazone in combination with losartan increases glucose compared to diabetic and Los-treated groups. Rosiglitazone significantly ameliorates endothelial dysfunction indicated by a significantly lower contractile response to PE and Ang II and enhancement of ACh-provoked relaxation in aortas isolated from diabetic rats[5]. |
| Kinase Assay | cDNA encoding amino acids 174-475 of PPARγ1 is amplified via polymerase chain reaction and inserted into bacterial expression vector pGEX-2T. GST-PPARγ LBD is expressed in BL21(DE3)plysS cells and extracts. For saturation binding analysis, bacterial extracts (100 μg of protein) are incubated at 4°C for 3 h in buffer containing 10 mM Tris (pH 8.0), 50 mM KCl, 10 mM dithiothreitol with [3H]-BRL49653 (specific activity, 40 Ci/mmol) in the presence or absence of unlabeled Rosiglitazone. Bound is separated from free radioactivity by elution through 1-mL Sephadex G-25 desalting columns. Bound radioactivity eluted in the column void volume and is quantitated by liquid scintillation counting[1]. |
| Cell Assay | C3H10T1/2 cells are grown in a 24-well plate in DME medium supplemented with 10% fetal calf serum. Medium and compound (Rosiglitazone) are exchanged every 3 days. Cells are stained at day 7 with Oil Red O and photographed[1]. |
| Animal Admin | Rats are intravenously injected with 38 mg/kg streptozotocin and after 48 h, diabetes is identified by urinary glucosuria and then random blood sugar is measured and this day is regarded as day 0. Animals with a serum glucose level of 220-300 mg/dL are selected to be used in this study. Rats are randomly separated into five groups for daily drug administration for 8 weeks: group 1: control nondiabetic rats given a vehicle only (0.5 mL/kg of 0.5% carboxy methyl celleluse orally), group 2: control diabetic rats given a vehicle, group 3: diabetic rats receiving Rosiglitazone (5 mg/kg orally), group 4: diabetic rats receiving losartan (2 mg/kg, orally), and group 5: diabetic rats receiving both Rosiglitazone and losartan[2]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 585.0±35.0 °C at 760 mmHg |
| Melting Point | 153-155ºC |
| Molecular Formula | C18H19N3O3S |
| Molecular Weight | 357.427 |
| Flash Point | 307.6±25.9 °C |
| Exact Mass | 357.114716 |
| PSA | 96.83000 |
| LogP | 2.56 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.642 |
| Storage condition | 2-8°C |
| Hazard Codes | Xi |
|---|---|
| Risk Phrases | R36/38 |
| Safety Phrases | S45-S28A-S20/21 |
| RIDADR | 3280 |
| Packaging Group | II |
| Hazard Class | 6.1 |
| HS Code | 2934999090 |
| Precursor 10 | |
|---|---|
| DownStream 1 | |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |